Clinical trial
A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)
NCT00482079 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00482079 |
|---|---|
| Title | A Study of MK0431 in Patients With Type 2 Diabetes (0431-010) |
| Official title | A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type II |
| Intervention type | Drug |
| Interventions | MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks |
| Enrollment | 743 |
| Start date | May 13, 2003 |
| Primary completion | Aug 25, 2004 |
| Completion | Jun 15, 2006 |
| First posted | Jun 4, 2007 |
| Last update posted | Mar 28, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: